- Funding
- $2.1B (2026)
Isomorphic Labs is a London-based drug-discovery company spun out of Google DeepMind that raised $2.1 billion in May 2026. By mid-2026 it was reportedly close to dosing patients in Phase 1 trials for AI-designed oncology candidates. Success before year-end would make it the first AI-native company to advance a self-designed drug from its own pipeline into the clinic.